FOR IMMEDIATE RELEASE
Jan. 16, 2024
Contact: Anthony Triana
atriana@saxum.com
(Direct) 405.818.0791
Cortado Ventures Invests in CorriXR: A Groundbreaking Gene-Editing Company with Initial Focus on Oncology
OKLAHOMA CITY – Cortado Ventures, a leading investment firm committed to supporting innovation and growth, announces a strategic investment in CorriXR Therapeutics, an oncology-focused biotherapeutics development company with a pioneering gene editing platform technology. This investment solidifies Cortado’s commitment to advancing cutting-edge medical solutions and supporting the development of groundbreaking treatments for cancer.
CorriXR Therapeutics, the inaugural biotech spin-out of ChristianaCare and the Gene Editing Institute, the only gene editing institute in the U.S. at a non-academic community-based hospital system, has developed a revolutionary gene editing platform utilizing a unique CRISPR/Cas biomolecular tool. The company’s initial focus is on treating squamous cell carcinoma of the lung, esophagus, and head and neck. The technology holds promise for a wide range of solid tumors, including glioma, pancreas, ovarian, bladder, melanoma, and thyroid cancers.
“We are excited to announce our investment in CorriXR Therapeutics, a company at the forefront of biotherapeutics development,” said Nathaniel Harding, Managing Partner at Cortado Ventures. “Their groundbreaking gene editing platform has the potential to revolutionize cancer treatment, offering hope to patients facing various solid tumors. Cortado is proud to support CorriXR’s mission to advance innovative and effective therapies. In addition, we are proud to support our Entrepreneur-in-Residence, Deborah Moorad, as she transitions into the role of CEO of CorriXR.”
CorriXR Therapeutics has achieved a significant milestone by receiving positive feedback from the FDA during an INTERACT meeting, prompting consideration for a basket trial encompassing lung, esophageal, and head and neck squamous cell carcinoma. CorriXR Therapeutics plans on a Pre-Investigational New Drug application (pre-IND) meeting this year, anticipating clinical trials starting the first quarter of 2025.
“The investment from Cortado will help us expand our oncology pipeline and prepare for our clinical launch,” Moorad said. “Our upcoming milestones include additional data for more tumor targets, and initiation of our first clinical trial. The Cortado investment is very instrumental in our development plan and reaching a critical inflection point — first in human clinical data.”
About Cortado Ventures
Cortado Ventures is an early-stage venture capital firm that invests in ambitious, growth-driven companies, backing a new generation of economic prosperity for the Midcontinent region, defined as Oklahoma, Texas, Arkansas, Missouri, Colorado, Kansas and New Mexico. As one of the largest VC funds in Oklahoma, Cortado’s focus is on tech companies bringing innovative solutions to the energy and logistics, life sciences, and the future of work sectors. For more information, visit cortado.ventures.
About CorriXR
CorriXR Therapeutics is an oncology-focused biotherapeutics development company enabled by a novel IP-protected in vivo gene editing therapeutic platform technology. CorriXR Therapeutics’ platform technology utilizes a proprietary CRISPR/Cas biomolecular tool to specifically disable the genome of a tumor cell while not affecting healthy cells. The initial CorriXR delivery system is a proven lipid nanoparticle approach that will evolve from direct injection into systemic delivery for other targets. For more information, visit https://www.corrixr.com/
###